ZA200800500B - Use of 4-(3,4 dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer - Google Patents

Use of 4-(3,4 dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer

Info

Publication number
ZA200800500B
ZA200800500B ZA200800500A ZA200800500A ZA200800500B ZA 200800500 B ZA200800500 B ZA 200800500B ZA 200800500 A ZA200800500 A ZA 200800500A ZA 200800500 A ZA200800500 A ZA 200800500A ZA 200800500 B ZA200800500 B ZA 200800500B
Authority
ZA
South Africa
Prior art keywords
naphtalen
ylamine
tetrahydro
dichloro
phenyl
Prior art date
Application number
ZA200800500A
Inventor
Revah Frederic
Balavoine Fabrice
Tuijnder Marius
Amson Robert
Telerman Adam
Original Assignee
Anceris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anceris filed Critical Anceris
Publication of ZA200800500B publication Critical patent/ZA200800500B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
ZA200800500A 2005-07-12 2005-07-12 Use of 4-(3,4 dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer ZA200800500B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507480A FR2888506A1 (en) 2005-07-12 2005-07-12 USE OF 4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDRO-NAPHTHALEN-1-YLAMINE FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
ZA200800500B true ZA200800500B (en) 2009-04-29

Family

ID=35925210

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800500A ZA200800500B (en) 2005-07-12 2005-07-12 Use of 4-(3,4 dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer

Country Status (14)

Country Link
EP (1) EP1904045A1 (en)
JP (1) JP2009501193A (en)
KR (1) KR20080031748A (en)
CN (1) CN101222917A (en)
AU (1) AU2006268657A1 (en)
CA (1) CA2614696A1 (en)
FR (1) FR2888506A1 (en)
IL (1) IL188685A0 (en)
MA (1) MA29729B1 (en)
NO (1) NO20080722L (en)
RU (1) RU2008101268A (en)
TN (1) TNSN08010A1 (en)
WO (1) WO2007006797A1 (en)
ZA (1) ZA200800500B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007233041B2 (en) * 2006-03-31 2013-05-02 Sepracor Inc. Preparation of chiral amides and amines
FR2909283A1 (en) * 2006-11-30 2008-06-06 Cerep Sa COMBINATION PRODUCT CONTAINING N-DESMETHYLSERTRALINE, OR ONE OF ITS SALT, AND AN ANNEOPLASTIC AGENT FOR THE TREATMENT OF CANCER
FR3071726B1 (en) * 2017-09-29 2020-09-04 Univ Paris Sud TCTP PROTEIN INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2265695A (en) * 1995-01-17 1996-08-07 Pfizer Inc. The use of sertraline to treat cancer patients
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
EP1660079A2 (en) * 2003-08-22 2006-05-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia

Also Published As

Publication number Publication date
KR20080031748A (en) 2008-04-10
MA29729B1 (en) 2008-09-01
WO2007006797A1 (en) 2007-01-18
NO20080722L (en) 2008-04-04
CN101222917A (en) 2008-07-16
JP2009501193A (en) 2009-01-15
WO2007006797A8 (en) 2007-04-19
AU2006268657A1 (en) 2007-01-18
TNSN08010A1 (en) 2009-07-14
FR2888506A1 (en) 2007-01-19
EP1904045A1 (en) 2008-04-02
CA2614696A1 (en) 2007-01-18
IL188685A0 (en) 2008-12-29
RU2008101268A (en) 2009-08-20

Similar Documents

Publication Publication Date Title
HK1127489A1 (en) Pyridiazinone derivatives for the treatment of tumours
HUE059861T2 (en) N-substituted 2,5-dioxo-azoline compounds for use in the treatment of cancer
HK1198922A1 (en) Compositions for treating or preventing oxalate-related disease
IL185215A0 (en) 2-cyanobenzenesulfonamide compounds for seed treatment
IL190882A0 (en) Compositions for cancer therapy
IL188430A0 (en) Treatment of tumors
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
IL187739A0 (en) New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
ZA200800907B (en) Treatment of cancer
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
PT1830847E (en) Treatment for cancer
HK1164767A1 (en) Compounds and methods for the treatment of cancer
IL177455A0 (en) Pyrazoline derivatives useful for the treatment of cancer
PL1895847T3 (en) Use of phenylsemicarbazones for seed treatment
GB0517387D0 (en) Combinations for the treatment of cancer
IL186020A0 (en) Oxaprozin or a closely related compound for the treatment of eczema
GB0803521D0 (en) A pharmaceutcal composition useful for the treatment of prostate cancer
ZA200800500B (en) Use of 4-(3,4 dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer
ZA200709959B (en) Triazine compounds and compositions thereof for the treatment of cancers
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0400802D0 (en) Compounds for the treatment of disease
IL226362A0 (en) Compounds, and methods for the treatment of cancer
GB0520067D0 (en) Treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
ZA200809565B (en) 4-(2, e-dichloro-benzoylamino)-1H-pyrazole-s-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the treatment of cancer